Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT06038539
Ignite Creation Date: 2024-05-06 @ 7:30 PM
Last Modification Date: 2024-10-26 @ 3:08 PM
Study NCT ID: NCT06038539
Protocol Section: NCT06038539
Start Identification Module Data
Expand Identification Module Data
Brief Title: Efficacy and Safety of the Proposed Biosimilar Pertuzumab PERT-IJS Versus EU-Perjeta Along With Trastuzumab and Chemotherapy Carboplatin and Docetaxel as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Official Title: A Multicenter Double-blind Randomized Parallel-group Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta Along With Trastuzumab and Chemotherapy Carboplatin and Docetaxel as Neoadjuvant Treatment in Patients With Hormone Receptor Negative HR-ve Human Epidermal Growth Factor Receptor 2 HER2-Positive Early Stage or Locally Advanced Breast Cancer
Acronym: None
Organization: Biocon Limited
Organization Class: INDUSTRY
Organization Study ID: BIO-PERTUZ-301
Start Status Module Data
Status Verified Date: 2024-04
Overall Status: NOT_YET_RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Biocon Biologics UK Ltd
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Biocon Biologics UK Ltd
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload